Clinical trial
A Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of GKL-006Allo Injection in Patients With Ankylosing Spondylitis
NCT07915544 is registered in ClinicalTrials.gov with Beijing Gene Key Life Technology Co., Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of GKL-006Allo Injection in Patients With Ankylosing Spondylitis
- Lead sponsor
- Beijing Gene Key Life Technology Co., Ltd
- Phase
- Phase 1
- Overall status
- Not yet recruiting
- Start date
- November 30, 2026
- Completion date
- March 30, 2028
- Enrollment
- 12 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
ankylosing spondylitis
Arms
As registered; 1 arm.
-
GKL-006Allo Injection
Participants receive GKL-006Allo injection by intravenous infusion once every two weeks for up to 11 doses. Participants are assigned to one of two dose levels, a low dose of (3.0±0.9)×10\^8 cells/m2 or a high dose of (9.0±2.7)×10\^8 cells/m2, with the low-dose level enrolled first and the high-dose level opened after safety review per the dose-escalation rules.
Primary endpoints
Registered primary outcome measures; 10 primary.
-
Dose-limiting toxicities (DLTs) of GKL-006Allo injection
Number and percentage of participants experiencing DLTs at each dose level during the DLT observation window, assessed per protocol-defined criteria.
-
Frequency of adverse events (AEs) and serious adverse events (SAEs)
Number and percentage of participants with AEs and SAEs, including treatment-emergent events, graded according to the Common Terminology Criteria for Adverse Events (CTCAE) v6.0.
-
Change from baseline in systolic blood pressure
Vital signs will be measured at each scheduled visit. Descriptive statistics will be provided for observed values and changes from baseline.Units: mmHg.
-
Change from baseline in diastolic blood pressure
Vital signs will be measured at each scheduled visit. Descriptive statistics will be provided for observed values and changes from baseline.Units: mmHg.
-
Change from baseline in pulse rate
Vital signs will be measured at each scheduled visit. Descriptive statistics will be provided for observed values and changes from baseline.Units: beats per minute (bpm).
+5 more primary endpoints
Lead sponsor's other trials
Beijing Gene Key Life Technology Co., Ltd, most recent start first.
+1 more trial
Similar trials
Same condition (Spondylitis, Ankylosing) and phase, most recent start first.
+13 more trials See the condition page